Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2019

21.08.2018 | Research Article

Lung cancer patients with a previous extra-pulmonary malignancy should not be considered homogeneous: a clinicopathological analysis of 3530 surgical cases

verfasst von: X.-L. Hu, S.-T. Xu, X.-C. Wang, D.-N. Hou, C. Bao, D. Yang, Y.-L. Song

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Lung cancer patients with a previous extra-pulmonary malignancy have been widely discussed for their postoperative prognosis. Still, whether different types of previous extra-pulmonary malignancy confer different clinicopathological features and outcomes of lung cancer patients deserves further investigation.

Methods

The medical records of patients undergoing operation for pulmonary malignancy were retrospectively reviewed. After identifying primary lung cancer out of pulmonary metastasis in patients with a history of previous extra-pulmonary malignancy, clinicopathological parameters and postoperative prognosis were compared between lung cancer patients without and with different types of previous extra-pulmonary malignancy.

Results

Approximately, 5.0% lung cancer patients undergoing surgery had a previous extra-pulmonary malignancy. Prior breast cancer (20%) and colorectal cancer (16%) formed the majority of these previous extra-pulmonary malignancies. Many clinicopathological features such as reason for visit, tumor size and histological subtype were significantly different between lung cancer patients without and with different types of previous extra-pulmonary malignancy (P < 0.05). Lung cancer patients with a previous occurrence of breast cancer were the most different type from patients without a previous extra-pulmonary malignancy in clinicopathological features (P < 0.05). The postoperative overall survival was not significantly different between lung cancer patients without and with different types of previous extra-pulmonary malignancy (P > 0.05).

Conclusion

Previous extra-pulmonary malignancy was confirmed to be harmless to postoperative prognosis of lung cancer patients. Lung cancer patients with a previous extra-pulmonary malignancy, especially with a previous occurrence of breast cancer, were highly heterogeneous in clinicopathological features. These findings implied there might be a unique etiology existing in lung cancer following a previous occurrence of breast cancer.
Literatur
1.
Zurück zum Zitat Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef
4.
Zurück zum Zitat Wu GX, Nelson RA, Kim JY, et al. Non-small cell lung cancer as a second primary among patients with previous malignancy: who is at risk? Clin Lung Cancer. 2017;18(5):543–50.CrossRefPubMedPubMedCentral Wu GX, Nelson RA, Kim JY, et al. Non-small cell lung cancer as a second primary among patients with previous malignancy: who is at risk? Clin Lung Cancer. 2017;18(5):543–50.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Halpenny DF, Cunningham JD, Long NM, et al. Patients with a previous history of malignancy undergoing lung cancer screening: clinical characteristics and radiologic findings. J Thorac Oncol. 2016;11(9):1447–52.CrossRefPubMedPubMedCentral Halpenny DF, Cunningham JD, Long NM, et al. Patients with a previous history of malignancy undergoing lung cancer screening: clinical characteristics and radiologic findings. J Thorac Oncol. 2016;11(9):1447–52.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hofmann HS, Neef H, Schmidt P. Primary lung cancer and extrapulmonary malignancy. Eur J Cardiothorac Surg. 2007;32(4):653–8.CrossRefPubMed Hofmann HS, Neef H, Schmidt P. Primary lung cancer and extrapulmonary malignancy. Eur J Cardiothorac Surg. 2007;32(4):653–8.CrossRefPubMed
7.
Zurück zum Zitat Shan S, She J, Xue ZQ, et al. Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies. PLoS One. 2017;12(9):e0185485.CrossRefPubMedPubMedCentral Shan S, She J, Xue ZQ, et al. Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies. PLoS One. 2017;12(9):e0185485.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pagès PB, Mordant P, Grand B, et al. History of multiple previous malignancies should not be a contraindication to the surgical resection of lung cancer. Ann Thorac Surg. 2013;95(3):1000–5.CrossRefPubMed Pagès PB, Mordant P, Grand B, et al. History of multiple previous malignancies should not be a contraindication to the surgical resection of lung cancer. Ann Thorac Surg. 2013;95(3):1000–5.CrossRefPubMed
9.
Zurück zum Zitat Reinmuth N, Stumpf P, Stumpf A, et al. Characteristics of lung cancer after a previous malignancy. Respir Med. 2014;108(6):910–7.CrossRefPubMed Reinmuth N, Stumpf P, Stumpf A, et al. Characteristics of lung cancer after a previous malignancy. Respir Med. 2014;108(6):910–7.CrossRefPubMed
10.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley; 2009. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley; 2009.
11.
Zurück zum Zitat Nakadate A, Nakadate M, Sato Y, et al. Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy. Gen Thorac Cardiovasc Surg. 2017;65(12):698–704.CrossRefPubMed Nakadate A, Nakadate M, Sato Y, et al. Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy. Gen Thorac Cardiovasc Surg. 2017;65(12):698–704.CrossRefPubMed
12.
Zurück zum Zitat Mery CM, Pappas AN, Bueno R, et al. Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. Chest. 2004;125(6):2175–81.CrossRefPubMed Mery CM, Pappas AN, Bueno R, et al. Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. Chest. 2004;125(6):2175–81.CrossRefPubMed
13.
Zurück zum Zitat Jin K, Wang K, Zhang H, et al. Solitary pulmonary lesion in patients with history of malignancy: primary lung cancer or metastatic cancer? Ann Surg Oncol. 2018;25:1237.CrossRefPubMed Jin K, Wang K, Zhang H, et al. Solitary pulmonary lesion in patients with history of malignancy: primary lung cancer or metastatic cancer? Ann Surg Oncol. 2018;25:1237.CrossRefPubMed
14.
Zurück zum Zitat Gerber DE, Laccetti AL, Xuan L, et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11):dju302.CrossRefPubMedPubMedCentral Gerber DE, Laccetti AL, Xuan L, et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11):dju302.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Laccetti AL, Pruitt SL, Xuan L, et al. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107(4):S56.CrossRef Laccetti AL, Pruitt SL, Xuan L, et al. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107(4):S56.CrossRef
16.
Zurück zum Zitat Laccetti AL, Pruitt SL, Xuan L, et al. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer. 2016;98:106.CrossRefPubMedPubMedCentral Laccetti AL, Pruitt SL, Xuan L, et al. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer. 2016;98:106.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Pruitt SL, Laccetti AL, Xuan L, et al. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer. 2017;116(6):717–25.CrossRefPubMedPubMedCentral Pruitt SL, Laccetti AL, Xuan L, et al. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer. 2017;116(6):717–25.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Hattori A, Suzuki K, Aokage K, et al. Prognosis of lung cancer patients with a past history of colorectal cancer. Jpn J Clin Oncol. 2014;44(11):1088–95.CrossRefPubMed Hattori A, Suzuki K, Aokage K, et al. Prognosis of lung cancer patients with a past history of colorectal cancer. Jpn J Clin Oncol. 2014;44(11):1088–95.CrossRefPubMed
19.
Zurück zum Zitat Pagès PB, Mordant P, Cazes A, et al. Prognosis of lung cancer resection in patients with previous extra-respiratory solid malignancies. Eur J Cardiothorac Surg. 2013;44(3):534–8.CrossRefPubMed Pagès PB, Mordant P, Cazes A, et al. Prognosis of lung cancer resection in patients with previous extra-respiratory solid malignancies. Eur J Cardiothorac Surg. 2013;44(3):534–8.CrossRefPubMed
20.
Zurück zum Zitat Quadrelli S, Lyons G, Colt H, et al. Lung cancer as a second primary malignancy: increasing prevalence and its influence on survival. Ann Surg Oncol. 2009;16(4):1033–8.CrossRefPubMed Quadrelli S, Lyons G, Colt H, et al. Lung cancer as a second primary malignancy: increasing prevalence and its influence on survival. Ann Surg Oncol. 2009;16(4):1033–8.CrossRefPubMed
21.
Zurück zum Zitat Schonfeld SJ, Curtis RE, Anderson WF, et al. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. Cancer Causes Control. 2012;23(10):1721–8.CrossRefPubMedPubMedCentral Schonfeld SJ, Curtis RE, Anderson WF, et al. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. Cancer Causes Control. 2012;23(10):1721–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Lung cancer patients with a previous extra-pulmonary malignancy should not be considered homogeneous: a clinicopathological analysis of 3530 surgical cases
verfasst von
X.-L. Hu
S.-T. Xu
X.-C. Wang
D.-N. Hou
C. Bao
D. Yang
Y.-L. Song
Publikationsdatum
21.08.2018
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1933-1

Weitere Artikel der Ausgabe 3/2019

Clinical and Translational Oncology 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.